Evidence map›Paper›PMID 32117463›Full record

ArticleFrontiers in genetics2020

Identification of Specific Long Non-Coding Ribonucleic Acid Signatures and Regulatory Networks in Prostate Cancer in Fine-Needle Aspiration Biopsies.

Zehuan Li, Jianghua Zheng, Qianlin Xia, Xiaomeng He, Juan Bao, Zhanghan Chen, Hiroshi Katayama, Die Yu, Xiaoyan Zhang, Jianqing Xu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Correlations of mInternational journal of general medicine · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Zehuan LiScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jianghua ZhengDepartment of Laboratory Medicine, Zhoupu Hospital Affiliated to Shanghai University of Medicine & Health Sciences, Shanghai, China.
Qianlin XiaDepartment of Laboratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Xiaomeng HeScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Juan BaoScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Zhanghan ChenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Hiroshi KatayamaDepartment of Molecular Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Die YuScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xiaoyan ZhangScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jianqing XuScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Tongyu ZhuScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jin WangScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Shanghai Public Health Clinical Center · CNSun Yat-sen University · CNOkayama University · JPShanghai Jiao Tong University · CNShanghai University of Medicine and Health Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is one of the most common tumors in men and can be lethal, especially if left untreated. A substantial majority of PCa patients not only are diagnosed based on fine needle aspiration (FNA) biopsies, but their treatment choices are also largely driven by the pathological findings obtained with these FNA specimens. It is widely believed that lncRNAs have strong biological significance, but their specific functions and regulatory networks have not been elucidated. LncRNAs may serve as key players and regulators of PCa carcinogenesis and could be novel biomarkers of this cancer. To identify potential markers for early detection of PCa, in this study, we employed a competing endogenous RNA (ceRNA) microarray to identify differentially expressed lncRNAs (DelncRNAs) in PCa tissue and quantitative real-time PCR (qRT-PCR) analysis to validate these DelncRNAs in FNA biopsies. We demonstrated that a total of 451 lncRNAs were differentially expressed in four pairs of PCa/adjacent tissues, and upregulation of the lncRNAs RP11-33A14.1, RP11-423H2.3, and LAMTOR5-AS1 was confirmed in FNA biopsies of PCa by qRT-PCR and was consistent with the ceRNA array data. The association between the expression of the lncRNA LAMTOR5-AS1 and aggressive cancer was also investigated. Regulatory network analysis of DelncRNAs showed that the lncRNAs RP11-33A14.1 and RP11-423H2.3 targeted miR-7, miR-24-3p, and miR-30 and interacted with the RNA binding protein FUS. Knockdown of these DelncRNAs in PCa cells also demonstrated the effects of RP11-423H2.3 on miR-7/miR-24/miR-30 or LAMTOR5-AS1 on miR-942-5p/miR-542-3p

Indexed as

biomarkerfine needle aspiration biopsieslong non-coding ribonucleic acidmicroribonucleic acidprostate cancerregulatory networksribonucleic acid binding proteins

Identifiers

PMID32117463
PMCPMC7034103
OpenAlexW3006250689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.